Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Company Deals

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

Fineline Cube Mar 30, 2026
Company Deals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Fineline Cube Mar 30, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Fineline Cube Mar 30, 2026
Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Fineline Cube Mar 30, 2026
Company

Everest Medicines CEO Resigns as Trodelvy Sale Completed

Fineline Cube Aug 26, 2022

China-based biotech Everest Medicines (HKG: 1952) announced the resignation of CEO Dr. Kerry Blanchard, effective...

Company Deals

Shanghai Bao Pharma Raises USD 100M in Series B to Advance Drug Delivery Tech

Fineline Cube Aug 26, 2022

Shanghai Bao Pharmaceuticals Co., Ltd has raised over USD 100 million in a Series B...

Company Deals

Lab Direct Raises USD 10M in Series A+ to Expand Digital Supply Chain Platform

Fineline Cube Aug 26, 2022

Shanghai-based life science digital supply chain platform Lab Direct has raised USD 10 million in...

Company Deals

Health Plus Receives Strategic Investment from Meinian Onehealth to Drive Healthcare Innovation

Fineline Cube Aug 26, 2022

Beijing-based Health Plus, a third-party digital managed healthcare service platform, has received strategic investment from...

Company Deals

Prismlab China Raises USD 29.1M in Series C for 3D Printing Expansion

Fineline Cube Aug 26, 2022

Shanghai-based 3D printing solution provider Prismlab China Ltd has raised RMB 200 million (USD 29.1...

Company Drug

Junshi Biosciences’ TAB009/JS009 and JS110 Advance in Cancer Trials

Fineline Cube Aug 26, 2022

Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...

Company

Illumina Opens First China Manufacturing Base for Gene Sequencers

Fineline Cube Aug 26, 2022

US-based Illumina (NASDAQ: ILMN) inaugurated its first manufacturing base in China on August 25, marking...

Company Drug

Junshi Biosciences Gets NMPA Go-Ahead for TAB009/JS009 Cancer Study

Fineline Cube Aug 26, 2022

Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...

Company

Illumina Opens First China Manufacturing Base for Gene Sequencers

Fineline Cube Aug 26, 2022

US-based Illumina (NASDAQ: ILMN) inaugurated its first manufacturing base in China on August 25, marking...

Company

Novartis to Spin Off Sandoz, Focus on Innovative Drugs

Fineline Cube Aug 26, 2022

Swiss drugmaker Novartis announced plans to spin off its generic and biosimilar unit, Sandoz, to...

Company Drug

Clover Biopharmaceuticals’ SCB-2019 Vaccine Proves Effective in Teenagers

Fineline Cube Aug 26, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) announced positive results from a global Phase II/III trial...

Company

CStone Pharmaceuticals’ H1 2022 Revenue Jumps 229% on Drug Sales Growth

Fineline Cube Aug 26, 2022

China-based CStone Pharmaceuticals (HKG: 2616) reported RMB 262 million (USD 49.4 million) in revenue for...

Company

Innovent Biologics’ H1 2022 Revenue Rises 15.3% on Drug Sales Growth

Fineline Cube Aug 26, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) reported RMB 2.24 billion (USD 326.4 million) in revenue...

Company

Akeso Biopharma’s H1 2022 Revenue Rises 26.8% on Penpulimab Sales

Fineline Cube Aug 25, 2022

China-based Akeso Biopharma (HKG: 9926) reported RMB 163 million (USD 23.8 million) in revenue for...

Company Drug

Alpha Biopharma Completes EVEREST Trial for Zorifertinib in EGFR+ NSCLC with CNS Metastases

Fineline Cube Aug 25, 2022

Shanghai-based Alpha Biopharma announced the completion of the last patient visit in the Phase II/III...

Company Deals

eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership

Fineline Cube Aug 25, 2022

Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million...

Company Drug

Sorrento Therapeutics’ Abivertinib Shows Positive Long-Term Data in NSCLC Trial

Fineline Cube Aug 25, 2022

Sorrento Therapeutics Inc. (OTCMKTS: SRNE) announced positive long-term results for its third-generation EGFR inhibitor abivertinib...

Company Deals

Porton Biologics and Royaltech Med Partner on Bacterial and mRNA Drug Platforms

Fineline Cube Aug 25, 2022

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has partnered with Suzhou...

Company Policy / Regulatory

NMPA Suspends UCB’s Keppra Over Labeling Issues, Prompting Recall

Fineline Cube Aug 25, 2022

The National Medical Products Administration (NMPA) has suspended approval for UCB’s Keppra (levetiracetam) concentrated solution...

Company Deals

Biocytogen and Merck KGaA Ink Global Deal for RenMice Platform Licensing

Fineline Cube Aug 25, 2022

Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has entered into a global...

Posts pagination

1 … 609 610 611 … 643

Recent updates

  • Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China
  • China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio
  • Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise
  • Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic
  • Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.